Company profile
Glycemicon AG
A financing round worth more than CHF 3 million, and clinical trials on both humans and cats: things are progressing nicely at Glycemicon. The startup is working on making a substance that occurs naturally in humans and animals and which is suitable for use in treating diabetes.
Source: startup.ch
Highlights
Top 100 Swiss Startup Award 2018
Top 100 Swiss Startup Award 2017
Top 100 Swiss Startup Award 2016
Top 100 Swiss Startup Award 2015
Top 100 Swiss Startup Award 2014
Winner Venture Kick
Innosuisse Certificate
Top 100 Swiss Startup Award 2013
More news about Glycemicon AG
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
